Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...

Did this woman’s additional bouts of pain warrant emergent repeat of previously negative angiography? Ms. P, a 54-year-old African American with a known history of hypertension, diabetes mellitus, and ...

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...

People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant reductions in ...

Depression can occur in approximately 1 in 5 patients who have chronic stable angina. After diagnosis of chronic stable angina, depression can occur in approximately 1 in 5 patients, according to a ...

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the ...

A new UK-led study has found that a procedure to reopen a fully blocked heart artery can significantly reduce chest pain and improve people’s quality of life. Researchers from Anglia Ruskin University ...

Refractory angina pectoris describes chronic chest pain in patients with advanced coronary artery disease who remain symptomatic despite optimal medical therapy and lack further revascularisation ...

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...